This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CEL-SCI Corporation Reports Third Quarter 2011 Financial Results

CEL-SCI Corporation (NYSE AMEX: CVM) reported today financial results for its third fiscal quarter for the period ended June 30, 2011.

CEL-SCI reported a net loss for the three months ended June 30, 2011 of ($3.1) million versus a loss of ($0.6) million during the same three months ended June 30, 2010. Net loss per basic share was ($0.01) for the three months ended June 30, 2011 versus a loss per basic share of ($0.00) during the same three months ended June 30, 2010.

Net loss for the nine months ended June 30, 2011 was ($23.4) million, versus a net income of $17.8 million during the same nine months ended June 30, 2010. Net loss per basic share was ($0.12) for the nine months ended June 30, 2011 versus a net income per basic share of $0.08 during the same nine months ended June 30, 2010.

R&D expenses for the three months ended June 30, 2011 totaled $2.9 million versus R&D expenses of $1.6 million for the same three months ended June 30, 2010. R&D expenses for the nine months ended June 30, 2011 totaled $9.2 million versus R&D expenses of $7.7 million for the same three months ended June 30, 2010.

Geert Kersten, Chief Executive Officer said, “Our Phase III clinical trial for head and neck cancer is proceeding well. So far, we have 22 centers that are enrolled in the study in eight countries. The centers are actively screening/enrolling patients. We have produced two clinical lots of Multikine ® from which patients are being treated.”

About CEL-SCI Corporation

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product, Multikine is currently being tested in a global Phase III clinical trial that started in December 2010. In Phase II clinical trials Multikine was shown to be safe and well-tolerated and to improve the patients overall survival by 33 percent at a median of three and half years following surgery.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs